TY - JOUR
T1 - Differences in the management and survival of metastatic colorectal cancer in Europe. A population-based study
AU - Working Group on Colorectum
AU - Bouvier, A. M.
AU - Jooste, V.
AU - Sanchez-Perez, Maria José
AU - Bento, M. J.
AU - Rocha Rodrigues, Jessica
AU - Marcos-Gragera, Rafael
AU - Carmona-Garcia, Maria Carmen
AU - Luque-Fernandez, Miguel Angel
AU - Minicozzi, P.
AU - Bouvier, V.
AU - Innos, K.
AU - Sant, Milena
AU - Van Eycken, L.
AU - Henau, K.
AU - Grozeva, T.
AU - Valerianova, Z.
AU - Innos, K.
AU - Mägi, M.
AU - Bouvier, V.
AU - Launoy, G.
AU - Robaszkiewicz, M.
AU - Bouvier, A. M.
AU - Jooste, V.
AU - Babaev, V.
AU - Katalinic, A.
AU - Ólafsdóttir, E. J.
AU - Tryggvadóttir, L.
AU - Amati, C.
AU - Baili, P.
AU - Bonfarnuzzo, S.
AU - Margutti, C.
AU - Meneghini, E.
AU - Minicozzi, P.
AU - Moretti, G.
AU - Sant, M.
AU - Cirilli, C.
AU - Carrozzi, G.
AU - Spata, E.
AU - Tumino, R.
AU - Rossi, P. Giorgi
AU - Vicentini, M.
AU - Stracci, F.
AU - Bianconi, F.
AU - Contiero, P.
AU - Tagliabue, G.
AU - Kycler, W.
AU - Oko, M.
AU - Macek, P.
AU - Smok-Kalwat, J.
AU - Bielska-Lasota, M.
N1 - Publisher Copyright:
© 2021
PY - 2021/5
Y1 - 2021/5
N2 - Background: The management regarding metastatic colorectal cancer throughout Europe is not well known. Aims: To draw a European comparison of the management and prognosis of metastatic colorectal cancers. Methods: Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model. Results: Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P<0.001) according to country. The 3-year net survival by country ranged between 16% and 37%. The survival gap between countries diminished from 21% to 10% when adjusting for chemotherapy, age and sex. Geographical differences in the crude probability of death related to cancer were large for patients <70 or ≥80 years at diagnosis. Conclusion: Heterogeneity in the application of European guidelines partly explain these differences. General health between populations, accessibility to a reference centre, or provision of health care could also be involved. Further population-based studies are warranted to disentangle between these possible explanations.
AB - Background: The management regarding metastatic colorectal cancer throughout Europe is not well known. Aims: To draw a European comparison of the management and prognosis of metastatic colorectal cancers. Methods: Factors associated with chemotherapy administration were identified through logistic regressions. Net survival was estimated and crude probabilities of death related to cancer and other causes using a flexible cumulative hazard model. Results: Among the 13 227 patients with colorectal cancer diagnosed between 2010 and 2013 in cancer registries from 10 European countries, 3140 were metastatic. 62% of metastatic patients received chemotherapy. Compared to Spain, the related adjusted odds ratios ranged from 0.7 to 4.0 (P<0.001) according to country. The 3-year net survival by country ranged between 16% and 37%. The survival gap between countries diminished from 21% to 10% when adjusting for chemotherapy, age and sex. Geographical differences in the crude probability of death related to cancer were large for patients <70 or ≥80 years at diagnosis. Conclusion: Heterogeneity in the application of European guidelines partly explain these differences. General health between populations, accessibility to a reference centre, or provision of health care could also be involved. Further population-based studies are warranted to disentangle between these possible explanations.
UR - http://www.scopus.com/inward/record.url?scp=85101391259&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/0aba8abf-06f4-3c63-a885-0e11a7e57057/
U2 - 10.1016/j.dld.2021.01.021
DO - 10.1016/j.dld.2021.01.021
M3 - Journal articles
C2 - 33637435
AN - SCOPUS:85101391259
SN - 1590-8658
VL - 53
SP - 639
EP - 645
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 5
ER -
